Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback